Dr. Gomella highlights his NYU GU 2022 presentations on bladder and prostate cancer
“The fascinating thing is that we have so many new treatments that are now available to us,” says Leonard G. Gomella, MD, FACS.
In this video, Leonard G. Gomella, MD, FACS, discusses key points from his 2 presentations, “Monitoring and Diagnosis of Non—Muscle-Invasive Bladder Cancer,” and “The Evolution of Biomarkers and Genetics in the Management of Prostate Cancer,” which were given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Gomella is the Bernard W. Godwin Professor of Prostate Cancer, chair of urology, and senior director for clinical affairs, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
